Clinical Trial Update: Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of Brexucabtagene Autoleucel in adults with rare B-cell malignancies has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Hairy Cell Leukemia
• Richter Transformation
• Waldenström Macroglobulinemia

Drugs mentioned

• Brexucabtagene Autoleucel (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | Phase 2 | Status: TERMINATED | Results posted: 2026-03-10